The shares ended the session at Rs 127 apiece on the S&P BSE Sensex on a day when the benchmark ended 226 points, or 0.41 per cent, higher
If demand remains good, investors can purchase at moderate valuations
The NSE and BSE said they had noticed some unregulated platforms and websites offering trading in unregulated derivative products called CFD/Binary Options
Anmi favours a model that may predict peak margins to be complied with by trading member so that on any given day upfront compliance may be considered based on margins for T-1 day
The entities will have to make a presentation to DIPAM on August 24-25
'Extraordinary scenario' say experts as both, short and long-duration funds give low returns
Including Monday's intra-day fall of 9.6 per cent, the stock of Ujjivan Small Finance Bank has tumbled 31 per cent in six days
Given the risk-aversion in markets, trading in equities may remain range-bound on Tuesday with stock-specific action in focus
The BSE barometer Sensex rose 226 points or 0.41% to 55,556. Nifty ended shy of 16,500 mark at 16,496, up 46 points or 0.28%
Riskier currencies, including the Aussie, Norwegian crown and the Canadian dollar were among the major beneficiaries of a weaker dollar in quiet London trading, rising more than 0.5% each
Sectorally, the Nifty IT index advanced 2 per cent while the Nifty Auto index tumbled 1.5 per cent
Gold exchange traded funds witnessed a pullout of over Rs 61 crore in July as investors diverted their money to equity and debt funds that generated attractive returns.
In the past one month, HCL Technologies has outperformed the market by surging 18 per cent at the bourses, as compared to 5 per cent rise in the S&P BSE Sensex.
On July 29, 2021 the board approved scheme of arrangement, which envisages the transfer of the entire balance of Rs 837.43 crore standing to the credit of the general reserve to the retained earnings
Ujjivan Small Finance Bank hit a new low of Rs 17.80, down 10% intra-day trade today, falling 27% in two days.
India Ratings & Research has downgraded the company's long term issuer rating to 'IND D', from 'IND A'
With this fundraise, the company completes the capital requirement needed for growth and navigating any uncertainties
The stock rebound from its opening level of Rs 471 and moved higher to Rs 538.60 on the BSE in intra-day trade
Aurobindo Pharma, on August 12, 2021, had entered into binding agreements with Cronus Pharma Specialities India Private Limited for acquisition of 51 per cent ownership
In the absence of any major domestic triggers, the equity market sentiment this week will be guided by the global trends. Volatility is likely to remain high amid rising global Covid cases and monthly